NCT02051218
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 50 versions: 41 with changes below, 9 re-verified with no change. See every version on ClinicalTrials.gov ↗
Stopped Trial terminated Sponsor's reason: Board decision as by March 2026, the number of patients undergoing treatment decreased to around 50, from the total 1,380 patients enrolled in the trial. And due to price changes in medication Show 4 more changesShow less
- Eligibility criteria expanded, about 24 words
- Primary completion date changed from estimate of Jun 30, 2026 to Mar 20, 2026
- Site details revised at 9 of 50 sites
- Publications: details revised at 1 of 1 entry
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 50 of 50 sites
- Minor Study sites revised (50)v45
- Minor Site details revised at 1 of 50 sitesv44
- Minor Site contacts updated at 1 of 50 sitesv42
Show 35 earlier versionsHide 35 earlier versions
- Notable Primary completion date: Dec 2022 to Jun 30, 2026
- Study completion date: Dec 2022 to Dec 31, 2028
- Study sites revised (50)
- Minor Site contacts updated at 2 of 50 sitesv40
- Minor Site contacts updated at 1 of 50 sitesv39
- Minor Study sites revised (50)v38
- Notable Trial status: Active, Not Recruiting to Recruiting
- Primary completion date: Dec 2021 to Dec 2022
- Enrollment target: 1181 to 1380
- Site details revised at 50 of 50 sites
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 1380 to confirmed 1181
- Site details revised at 50 of 50 sites
- Minor Site contacts updated at 2 of 50 sitesv32
- Minor Site contacts updated at 1 of 50 sitesv31
- Minor Site contacts updated at 1 of 50 sitesv30
- Notable Primary completion date: Dec 2019 to Dec 2021v29
- Minor Study sites: 49 to 50v27
- Minor Site details revised at 2 of 49 sitesv26
- Minor Study sites: 48 to 49v25
- Minor Study sites: 47 to 48v24
- Minor Site contacts updated at 1 of 47 sitesv23
- Minor Site contacts updated at 1 of 47 sitesv22
- Minor Study sites: 46 to 47v21
- Minor Site contacts updated at 1 of 46 sitesv20
- Minor Study sites: 45 to 46v19
- Minor Study sites: 40 to 45
- Secondary endpoints revised (8)
- Minor Study sites: 39 to 40v17
- Minor Study sites revised (39)v16
- Minor Study sites: 32 to 39
- Start date: Jul 2014 to Jul 16, 2014
- Minor Site contacts updated at 1 of 32 sitesv14
- Minor Site details revised at 6 of 32 sitesv13
- Minor Study sites: 30 to 32v12
- Minor Study sites: 29 to 30v11
- Minor Site details revised at 1 of 29 sitesv10
- Minor Study sites: 28 to 29v9
- Minor Site contacts updated at 1 of 28 sitesv8
- Minor Site contacts updated at 1 of 28 sitesv6
- Minor Study sites: 26 to 28v5
- Notable Eligibility criteria expanded, about 28 words
- Secondary endpoints revised (8)
- Minor Study sites: 7 to 26v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Apr 2014 to Jul 2014
- Study sites: 3 to 7
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Time to first on-trial symptomatic skeletal event (SSE; Clinically significant pathological fracture, radiation therapy to bone, surgery to bone or spinal cord compression).
Timeframe: at the latest 5 years after randomization.
Secondary (8)
Toxicity (focus on hypocalcaemia and osteonecrosis of the jaw)
Time to first and subsequent on-trial SSE
Quality of Life measured by FACT-G and FACT-BP
Skeletal morbidity period rate (SMPR)
Skeletal morbidity rate (SMR)
Show 3 moreShow less
Health economic analysis
Bone turnover markers
Overall Survival (OS)
Arms and interventions
Arm A (standard arm)Active comparator
Denosumab 120mg (XGEVA®) sc. q4w
Arm B (reduced arm)Experimental
Denosumab 120mg (XGEVA®) sc. q4w \[weeks 1, 5, 9\] followed by Denosumab 120mg (XGEVA®) sc. q12w \[weeks 13, 25, …\]
Drugs: Denosumab (reduced dosing), Denosumab (standard dosing)
Sites
50 sites in 3 countries
Switzerland 43, Germany 5, Austria 2